Results 241 to 250 of about 3,688,287 (401)

Clinical Evaluation of Severe Asthma Attacks Requiring Tracheal Intubation and Mechanical Ventilation

, 2009
Kiyoshi Sekiya, Keishi Sugino, Takako Hojyo, Fumiaki Ishida, Go Sano, Kazunori Isobe, Kazuhiro Kimura, Masami Taniguchi, Kazuo Akiyama, Sakae Homma   +9 more
openalex   +1 more source

Self‐Management Interventions in Young Adults (18–30 Years) With Type 1 Diabetes, Sickle Cell Disease, and Inflammatory Bowel Disease: A Scoping Review

Chronic Diseases and Translational Medicine, EarlyView.
ABSTRACT Fluctuating chronic conditions (FCC) in young adults aged 18–30 years, such as type 1 diabetes (T1D), sickle cell disease (SCD), and inflammatory bowel disease (IBD), present unique self‐management challenges due to unpredictable symptom patterns that disrupt daily life.
Reham Almabadi, Lawrence Doi, Colin Chandler, Huda Alamri   +3 more
wiley   +1 more source

Comparative analysis of the manufacturing carbon footprint of biologics for severe asthma. [PDF]

BMJ Open
Taylor H, Rahman N.
europepmc   +1 more source

Identification of TXN and F5 as novel diagnostic gene biomarkers of the severe asthma based on bioinformatics and machine learning analysis

Lu Shou, Haidong He, Wei Yi, Xianrong Xu, Wenmin Wang, Jisheng Zheng   +5 more
openalex   +1 more source

Long-Term Natural History of Severe Asthma Exacerbations and Their Impact on the Disease Course

, 2021
Tae Yoon Lee, John Petkau, Mohsen Sadatsafavi   +2 more
openalex   +2 more sources

Neutrophilic asthma: a complex phenotype of severe asthma [PDF]

, 2020
Nightingale Syabbalo
openalex   +1 more source

The Prevalence and Implications of Polypharmacy in Individuals With Type 1 Diabetes

Clinical Pharmacology &Therapeutics, EarlyView.
Polypharmacy is increasingly recognized as a relevant issue in diabetes care, but its prevalence and clinical relevance in individuals with type 1 diabetes remain underexplored. This study aimed to determine the prevalence of polypharmacy and to identify associated clinical and psychological factors. Participants were recruited from a tertiary diabetes
Namam Ali, Stephan van Erp, Cornelis Kramers, Cornelis J. Tack, Bastiaan E. de Galan   +4 more
wiley   +1 more source

Treatment of Severe Asthma Is Not "Cookie-Cutter" Medicine. [PDF]

Am J Respir Crit Care Med
Busse WW, Viswanathan R.
europepmc   +1 more source

PRP10: PREDICTING THE BENEFIT OF OPTIMIZING SEVERE ASTHMA MANAGEMENT IN A MANAGED CARE SETTING:A COST-BENEFIT ANALYSIS COMPARING THE COMBINATION OF FLUTICASONE PROPIONATE AND SALMETEROL (FPS) AND ZAFIRLUKAST

, 2003
A Joglekar, Chih-Chung Chao, P Kadison
openalex   +1 more source

Verekitug, a Novel Antibody Antagonist to the TSLP Receptor in Adults with Asthma: A 32‐Week Randomized Phase 1b Multiple Ascending‐Dose Trial

Clinical Pharmacology &Therapeutics, EarlyView.
Verekitug, a novel, high‐affinity, fully human monoclonal antibody targeting thymic stromal lymphopoietin receptor (TSLPR), is in development as a potential treatment for severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and chronic obstructive pulmonary disease (COPD).
Dave Singh, Chaim M. Brickman, Peter Lloyd, Ashish Kalra, Subhabrata Biswas, Arkadeep Sinha, Alex Mulvanny, Sumathi Sivapalasingam, Oren M. Becker, Aaron Deykin   +9 more
wiley   +1 more source